BR112015029691A2 - novos compostos 3,4-dihidro-2h-isoquinolina-ona e 2,3-dihidro-isoindol-1-ona - Google Patents
novos compostos 3,4-dihidro-2h-isoquinolina-ona e 2,3-dihidro-isoindol-1-onaInfo
- Publication number
- BR112015029691A2 BR112015029691A2 BR112015029691A BR112015029691A BR112015029691A2 BR 112015029691 A2 BR112015029691 A2 BR 112015029691A2 BR 112015029691 A BR112015029691 A BR 112015029691A BR 112015029691 A BR112015029691 A BR 112015029691A BR 112015029691 A2 BR112015029691 A2 BR 112015029691A2
- Authority
- BR
- Brazil
- Prior art keywords
- dihydro
- isoindol
- isoquinoline
- new compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1/1 resumo novos compostos 3,4-dihidro-2h-isoquinolina-ona e 2,3-dihidro-isoindol-1-ona" a presente invenção fornece novos compostos da fórmula (i): em que: r10 r11 r12 r1r2r3 r4r5r6r7r8r9 ,, e ,,,,,,,, r13 , r14, r15, a, m, n e p são conforme descrito no presente documento, e composições incluindo os compostos e métodos de uso dos compostos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/076285 | 2013-05-27 | ||
| CN2013076285 | 2013-05-27 | ||
| PCT/EP2014/060794 WO2014191340A1 (en) | 2013-05-27 | 2014-05-26 | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015029691A2 true BR112015029691A2 (pt) | 2017-07-25 |
| BR112015029691B1 BR112015029691B1 (pt) | 2023-03-28 |
Family
ID=50819739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015029691-2A BR112015029691B1 (pt) | 2013-05-27 | 2014-05-26 | Compostos 3,4-dihidro-2h-isoquinolina-ona e 2,3-dihidro-isoindol-1-ona |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9695152B2 (pt) |
| EP (1) | EP3004076B1 (pt) |
| JP (2) | JP6416230B2 (pt) |
| AR (1) | AR096425A1 (pt) |
| BR (1) | BR112015029691B1 (pt) |
| CA (1) | CA2902848C (pt) |
| DK (1) | DK3004076T3 (pt) |
| ES (1) | ES2763424T3 (pt) |
| HK (1) | HK1213556A1 (pt) |
| HR (1) | HRP20192242T1 (pt) |
| HU (1) | HUE046739T2 (pt) |
| LT (1) | LT3004076T (pt) |
| MX (1) | MX368759B (pt) |
| PL (1) | PL3004076T3 (pt) |
| PT (1) | PT3004076T (pt) |
| RS (1) | RS59663B1 (pt) |
| RU (1) | RU2693698C2 (pt) |
| SI (1) | SI3004076T1 (pt) |
| TW (1) | TWI704143B (pt) |
| WO (1) | WO2014191340A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6416229B2 (ja) * | 2013-05-27 | 2018-10-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| ES2850198T3 (es) * | 2014-10-08 | 2021-08-26 | Hoffmann La Roche | Derivados de espirodiamina como inhibidores de la aldosterona sintasa |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2627648A1 (en) * | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| KR101785143B1 (ko) * | 2011-09-15 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | 다이하이드로퀴놀린-2-온 유도체 |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2014
- 2014-05-26 RS RS20191616A patent/RS59663B1/sr unknown
- 2014-05-26 CA CA2902848A patent/CA2902848C/en active Active
- 2014-05-26 EP EP14726363.6A patent/EP3004076B1/en active Active
- 2014-05-26 DK DK14726363.6T patent/DK3004076T3/da active
- 2014-05-26 ES ES14726363T patent/ES2763424T3/es active Active
- 2014-05-26 MX MX2015015058A patent/MX368759B/es active IP Right Grant
- 2014-05-26 PT PT147263636T patent/PT3004076T/pt unknown
- 2014-05-26 LT LTEP14726363.6T patent/LT3004076T/lt unknown
- 2014-05-26 BR BR112015029691-2A patent/BR112015029691B1/pt active IP Right Grant
- 2014-05-26 WO PCT/EP2014/060794 patent/WO2014191340A1/en active Application Filing
- 2014-05-26 PL PL14726363T patent/PL3004076T3/pl unknown
- 2014-05-26 JP JP2016515760A patent/JP6416230B2/ja active Active
- 2014-05-26 TW TW103118319A patent/TWI704143B/zh active
- 2014-05-26 HU HUE14726363A patent/HUE046739T2/hu unknown
- 2014-05-26 RU RU2015149956A patent/RU2693698C2/ru active
- 2014-05-26 SI SI201431431T patent/SI3004076T1/sl unknown
- 2014-05-26 AR ARP140102073A patent/AR096425A1/es active IP Right Grant
-
2015
- 2015-11-20 US US14/947,768 patent/US9695152B2/en active Active
-
2016
- 2016-02-11 HK HK16101487.0A patent/HK1213556A1/zh unknown
-
2018
- 2018-10-03 JP JP2018188236A patent/JP2019014738A/ja active Pending
-
2019
- 2019-12-12 HR HRP20192242TT patent/HRP20192242T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019014738A (ja) | 2019-01-31 |
| AR096425A1 (es) | 2015-12-30 |
| US9695152B2 (en) | 2017-07-04 |
| MX2015015058A (es) | 2016-02-11 |
| CA2902848A1 (en) | 2014-12-04 |
| JP6416230B2 (ja) | 2018-10-31 |
| HUE046739T2 (hu) | 2020-03-30 |
| EP3004076B1 (en) | 2019-10-23 |
| ES2763424T3 (es) | 2020-05-28 |
| JP2016520106A (ja) | 2016-07-11 |
| DK3004076T3 (da) | 2020-01-02 |
| LT3004076T (lt) | 2020-01-10 |
| US20160075688A1 (en) | 2016-03-17 |
| RU2693698C2 (ru) | 2019-07-04 |
| HRP20192242T1 (hr) | 2020-03-06 |
| EP3004076A1 (en) | 2016-04-13 |
| WO2014191340A1 (en) | 2014-12-04 |
| SI3004076T1 (sl) | 2020-02-28 |
| BR112015029691B1 (pt) | 2023-03-28 |
| PL3004076T3 (pl) | 2020-04-30 |
| TW201534596A (zh) | 2015-09-16 |
| TWI704143B (zh) | 2020-09-11 |
| HK1213556A1 (zh) | 2016-07-08 |
| CA2902848C (en) | 2021-09-21 |
| MX368759B (es) | 2019-10-15 |
| RU2015149956A3 (pt) | 2018-03-19 |
| RU2015149956A (ru) | 2017-07-04 |
| PT3004076T (pt) | 2019-12-18 |
| RS59663B1 (sr) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
| CL2016001120A1 (es) | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct | |
| BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
| BR112014017021A2 (pt) | inibidores de irak e usos dos mesmos | |
| BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| BR112017006829A2 (pt) | derivados de espirodiamina como inibidores de aldosterona sintase | |
| EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
| BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
| EA201590534A1 (ru) | Новые бициклические производные | |
| BR112015028152A2 (pt) | inibidores de acc e usos dos mesmos | |
| BRPI0914682B8 (pt) | compostos de heteroarila e composições compreendendo os referidos compostos | |
| EA201591527A1 (ru) | Новые производные пиридина | |
| BR112014006283A2 (pt) | novos derivados de dihidroquinolina-2-ona | |
| BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
| BR112019006571A2 (pt) | derivados de éter de isoxazolila como gaba a alfa5 pam | |
| EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
| EA201591451A1 (ru) | Модуляторы flap | |
| EA201490846A1 (ru) | Новые производные арилхинолина | |
| BR112016007757A8 (pt) | Derivados antibacterianos de 2h-indazol | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
| BR112015023829A2 (pt) | composto de amidina e seu uso | |
| BR112015007879A2 (pt) | inibidores do vírus da hepatite c | |
| EA201500821A1 (ru) | Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов | |
| CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2014, OBSERVADAS AS CONDICOES LEGAIS |